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Volume 52, Number 6 Abstracts 1745Conclusions: Despite a constant number of yearly intact AAA repair,
national EVAR utilization increased over the study period. Perioperative
mortality was lower after EVAR but there was no difference in long-term
survival and no regional differences in mortality for either cohort. In
addition, EVAR was performed with a lower hospital cost than OPEN. This
large national study further supports the use of EVAR as the first-line therapy
for intact AAA.
Midwest Northeast South West National
Number of patients OPEN 10,195 6175 13,571 4722 34,663
EVAR 18,433 13,012 28,102 8,823 68,370
%EVAR 64.4% 67.8% 67.4% 65.1% 66.4%
P  .001
30-mortality OPEN 4.9% 4.8% 5.0% 4.6% 4.9%
EVAR 2.6% 1.9% 2.4% 2.5% 1.6%
P  .001 (OPEN vs EVAR)
5-year survival OPEN 74.4% 73.8% 72.7% 74.1% 73.6%
EVAR 75.5% 73.6% 74.1% 75.3% 74.6%
(P  .4 for OPEN vs EVAR, P  .9 for regions)
Randomized Clinical Trial of Open-Cell vs Closed-Cell Stents for
Carotid Stenting: Effects of Stent Design on Cerebral Embolization
Carlos H. Timaran, Eric B. Rosero, Adriana Higuera, Adriana Ilarraza, J.
Gregory Modrall, G. Patrick Clagett, University of Texas, SW Medical
Center, Dallas, Tex
Background: The effect of stent design on cerebral embolization has
not been established. The purpose of this trial was to contrast the incidence
of cerebral embolization in high-risk patients undergoing carotid artery
stenting (CAS) with open-cell vs closed-cell stents.
Methods: During an 18-month period, 40 patients were randomized
(1:1) to undergo CASwith open-cell (Acculink, n 20) or closed-cell stents
(Xact, n  20). A single filter device for embolic protection (Accunet filter)
was used. Transcranial Doppler (TCD)-detected microembolic signals
(MES) during CAS and pre- and 24-hour postprocedural diffusion-
weighted magnetic resonance imaging (DW-MRI) were used to determine
cerebral embolization. Univariate and nonparametric analyses were used to
assess associations between stent design and cerebral embolization.
Results: CAS was performed in 16 (41%) symptomatic and 24 (59%)
asymptomatic patients with equal number of open-cell and closed-cell stents
(8/8 and 12/12, respectively). The total and poststenting median MES
counts detected by TCD were 225 (interquartile range [IQR], 191-257)
and 59 (IQR, 43-123) for open-cell stents and 281 (IQR, 134-372) and 74
(IQR, 41-88) for closed-cell stents, respectively (P .4). New acute cerebral
emboli detected with DW-MRI occurred in 47% and 53% of patients
undergoing CAS with open-cell and closed-cell stents, respectively (P .9).
The total and ipsilateral median number of DW-MRI lesions between
groups were not statistically significantly different, ie, 1.5 (IQR, 0-3.75) and
1 (IQR, 0-2) for open-cell stents and 2 (IQR, 0-3) and 1 (IQR, 0-3) for
closed cell-stents, respectively (P  .7). One asymptomatic patient under-
going CAS with an open-cell stent sustained a minor stroke; the 30-day
stroke-death rate in this series was 2.5%.
Conclusions: Cerebral embolization, as detected by TCD and DW-
MRI, occurs with similar frequency after CAS with open-cell and closed-cell
stents. This randomized trial does not support the superiority of any stent
design with respect to cerebral embolization.
Timing of Venous Thromboembolism After Colorectal Cancer Resec-
tion
Eleftherios Xenos, Daniel L. Davenport, David J. Minion, Ehab E. Sorial,
Shane D. O’Keeffe, Eric D. Endean, University of Kentucky Medical Cen-
ter, Lexington, Ky
Background: Deep vein thrombosis (DVT) and pulmonary embolism
(PE) are significant sources of postoperative morbidity and mortality and are
currently major quality improvement initiatives. Mechanical and pharmaco-
logical prophylaxis is effective in preventing postoperative thromboembolic
events, thromboprophylaxis is usually discontinued after discharge. We
postulated that patients may still be at risk of venous thromboembolic
disease (VTE) after discharge and and tested this hypothesis in patients
undergoing colorectal resection for cancer, a high-risk population.
Methods: The ACS NSQIP database was queried for patients under-
going colorectal resections for cancer based on the primary procedure CPT
code and operative ICD-9 diagnosis code from 2005 to 2008. The outcome
analyzed was 30-day DVT and/or PE. DVT/PE occurrences were analyzed
by postoperative day, rate relative to hospital length of stay, and by whether
they occurred in-hospital or after initial discharge. Multivariable forward
stepwise regression (P for entry  .05, for exit  .10) was used to identify
independent predictors of DVT.Results: The database contained 21,943 colorectal cancer resections.
DVT/PE (both inpatient and outpatient) rates increased linearly from 0.8%
in patients with length of stay (LOS) less than 1 week to 11.6% in patients
with LOS greater than 3weeks (2 test for linear trend, P .001, Fig 1). The
DVT rate was 1.4% (306/21,943) of which 29% (89/306) were diagnosed
post discharge. The PE rate 0.8% (180/21,943) of which 33% (60/180)
were diagnosed post discharge. Patients were diagnosed with both only 40
times and the combined DVT or PE rate was 2.0% (446/21,943). The ratio
of outpatient to inpatient VTE rate as related to days that elapsed from the
surgical procedure is shown in Figure 2. Independent risk factors for
postdischarge DVT/PE were preoperative steroid use for chronic condition
(n  575, odds ratio 2.90, 95% CI 1.51-5.57, P  .001) and preoperative
systemic inflammatory response syndrome (n  875, odds ratio 2.26, 95%
CI 1.24-4.10, P  .008)
Conclusions:Analysis of theNSQIP database shows increasing rates of
VTE as hospital LOS increases. It was surprising to find that diagnosis of
almost 1/3 of postoperative VTE in this patient population occurs after
discharge. The duration of the prothrombotic stimulus of surgery is not well
defined and patients with malignancy are at high risk of VTE. It is conceiv-
able that thromboprophylaxis after discharge should be considered for these
patients. Additional studies may identify other patient groups in similar risk.
Diastolic Function Predicts Survival After Renal Revascularization
Racheed J. Ghanami1, Hamza Rana1, Tim Craven1, Matthew A Corriere2,
Phillip Moore1, John Hoyle1, Randolph L. Geary1, Matthew S Edwards1,
Christopher J Godshall1, Kimberley J. Hansen1, 1Wake Forest University
Baptist Medical Center, Winston-Salem, NC; 2Emory University School of
Medicine, Atlanta, Ga
Background: To define the relationship between left ventricular dia-
stolic function and survival after renal revascularization.
Methods: Seventy-six adult patients (49 women, 27 men; mean age:
63 years  13 years) with preoperative echocardiography who underwent
renal revascularization for atherosclerotic disease were identified. Echocar-
diograms were performed and interpreted according to American Society of
Echocardiography Recommendations for Use of Echocardiography in Clin-
ical Trials. Diastolic function was estimated by measuring the early diastolic
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mitral annular tissue doppler velocity (e=). Patients were divided into two
groups of diastolic dysfunction as either none/mild (E/A  0.75, E/e= 
10) or moderate/severe (E/A  0.75, E/e=  10). Perioperative and
long-term mortality was determined from a prospective vascular database
and the National Death Index. Descriptive statistics were calculated. Post-
operative survival was estimated by product-limit methods. Associations
between preoperative and perioperative factors and long-term survival were
examined using proportional hazards regression models. A backwards vari-
able elimination procedure was used to select a ‘best’ model to predict
long-term survival.
Results: Seventy-six patients were followed for an average of 41.9
months after renal revascularization. Within this group, 47/76 (61.8%)
patients were identified as having moderate or severe diastolic dysfunction.
Systolic function was preserved. The mean ejection fraction for the entire
group was 58.3%  11.1%. Diastolic dysfunction had no apparent associa-
tion with abnormal systolic function. The mean ejection fraction for those
with moderate/severe diastolic dysfunction was 57.7%  11.5%. When
comparing the moderate/severe and none/mild groupings of diastolic
dysfunction, there was a significant difference in left ventricular mass index
(151.9  48.9 vs 125.3  31.7, P  .0087). There were five deaths in the
perioperative period and 20 deaths on follow-up. Among survivors, hyper-
tension was cured or improved in 82% of the none/mild group and 53% of
the moderate/severe group (P  .012). Renal function was improved in
32% of the none/mild group and 26% of the moderate/severe group (P 
.54).Multivariate analysis among 71 perioperative survivors demonstrated a
significant and independent association between diastolic dysfunction and
survival (HR 5.1, 95% CI 1.1-23.6, P .037) (Fig 1). Ejection fraction did
not have a significant effect on long-term survival. Backward elimination
resulted in a final model that included diastolic dysfunction (HR 5.8, 95%CI
1.4-25, P .018) and history of stroke/TIA (HR 2.5, 95% CI 0.9-7.1, P
.092) as the only signficant predictors of long-term survival.
Conclusions: Diastolic dysfunction, but not systolic function, was
frequent in patients with renovascular disease. After renal revascularization,
diastolic function had a significant and independent association with long-
term survival. Preoperative assessment of diastolic function should be con-
sidered in patients prior to surgical repair.
Treatment of Proximal Vertebral Artery Disease
Joshua L. Gierman, Karen McQuade, William Shutze, Stephen Hohmann,
Gregory Pearl, Bertram Smith, Dennis Gable, Bradley Grimsley, John
Kedora, Toby Dunn, Baylor University Medical Center, Dallas, Tex
Background: Vertebral arterial disease (VAD) is a less commonly
recognized and treated source of cerebro-vascular ischemia compared to
carotid artery disease. Patients are often referred for treatment after they
have developed symptoms in the form of TIA or have had a posterior
hemispheric stroke. Traditional treatment of VAD has been surgical. More
recently, endovascular treatment of VAD has been utilized.
Methods: We performed a retrospective review of our institutional
experience in treating proximal VAD from 2001 to 2010. After obtaining
IRB approval, 53 patients were identified for review. Hospital and office
record data from the Division of Vascular Surgery and the Department of
Radiology was reviewed.
Results: Thirty-six patients had surgery and seventeen patients had
endovascular therapy. All patients in the surgical arm were symptomatic.
Symptoms included: ataxia (56%), dizziness (19%), syncope (11%), visual
symptoms (13.8%), and major stroke (8.3%) Fifteen of the patients in the
endovascular arm were symptomatic. Symptoms included: major stroke
(40%), visual symptoms (13.3%), dizziness (13.3%), ataxia (6.7%), and
syncope (6.7%). Demographics of the surgical and endovascular patients
were similar for: age (68.3 vs 62.2 years), CAD (58% vs 65%), HTN (78% vs
76%), DM (41% vs 53%), and history of tobacco use (75% vs 70%). Incidence
of major stroke prior to treatment was lower in the surgical group (8.3% vs
40%). In the surgical group: average length of stay was 2.1 days. There weremajor complications in two patients (5.6%). Complications included: bleed-
ing requiring re-intubation and surgical evacuation, and myocardial infarc-
tion (which caused the one death [2.8%]). Symptoms were relieved com-
pletely in 86%, partially in 5.6% and not at all in 8.3% of patients. In the
endovascular group, average length of stay was 5.8 days. There were no
major periprocedural complications, however, 6-week mortality was 11.7%.
Symptoms resolved completely in 27%, partially in 63%, and not at all in 9%
of symptomatic patients.
Conclusions: For treatment of proximal VAD, perioperativemorbidity
was lower for the endovascular group than the surgical group, but the
6-week mortality was higher for this treatment modality. Complete resolu-
tion of symptoms occurred more frequently with surgery than with endo-
vascular therapy (86% vs 27%). Therefore, in general, surgical reconstruction
appears to be preferable to angioplasty and stenting for the treatment of
proximal vertebral artery occlusive disease.
Outcomes of Acute Surgical Conversion during Endovascular Aortic
Aneurysm Repair
William B. Newton, III1, Jeanette S. Andrews1, Matthew A. Corriere2,
Philip P. Goodney3, Racheed J. Ghanami1, Randolph L. Geary1, Christo-
pher J. Godshall1, Kimberley J. Hansen1, Matthew S. Edwards1, 1Wake
Forest University Baptist Medical Center, Winston-Salem, NC; 2Emory
University School of Medicine, Atlanta, Ga; 3Dartmouth-Hitchcock Medi-
cal Center, Lebanon, NH
Background: Acute surgical conversion during endovascular aortic
aneurysm repair (EVAR) is uncommon. Outcomes and predictors of intra-
operative conversion are unknown. This report examines EVAR conversions
using the American College of Surgeons National Surgical Quality Improve-
ment Program Database for years 2005-2008.
Methods: Conversion cases occurring during elective EVAR were
identified using CPT codes. Nonemergent EVAR and primary open surgical
repairs of infrarenal aneurysms were also examined for comparison. Periop-
erative morbidity was categorized as: wound, pulmonary, venous thrombo-
embolic, genitourinary, cardiovascular, operative, and septic. Mortality,
overall morbidity, and length of stay (LOS) were also examined. Differences
among repair groups for descriptive and outcome variables were evaluated
using 2 tests, and linear or logistic regressions. Predictors of conversion
were also evaluated using logistic regression.
Results: Seventy-two conversions, 2414 open repairs, and 6332
EVARs were identified. Demographics and comorbidities were generally
similar among operative groups. Mean operative time for conversion cases
was 274 113 minutes compared to 226 93 minutes for open repair and
162  74 minutes for EVAR cases (conversion vs EVAR and open repair vs
EVAR (P  .0001 for each], and conversion vs open repair P  .0014;
analysis on rank operative time). Sixty-nine percent of patients undergoing
conversion required red blood cell transfusion with a mean volume of 6.0
6.3 units vs 73% of open repairs (mean volume 3.3 3.3 units), and 12% of
EVAR (mean volume of 2.6  2.5 units) (P  .0001 for each pair-wise
comparison; analysis on rank number of units among those transfused).
Major morbidity occurred in 28% of conversions, 28% of open repairs, and
12% of EVARs. Mortality was 4.2% for conversions, 3.2% for open repairs,
and 1.3% for EVARs.Median (Q1,Q3) LOSwas 7 (5, 9) days for conversion
and open repair, and 2 (1, 3) days for EVAR. Morbidity and mortality were
significantly higher for conversion and open repair vs EVAR (OR [95%CI]
for morbidity 2.9 [1.7, 4.8] and 2.8 [2.5, 3.2], for conversion and open
repair, respectively [P  .0001 for both]: OR [95% CI] for mortality 3.4
[1.0, 10.9] P .0437 and 2.5 [1.9, 3.5] P .0001, for conversion and open
repair, respectively). Morbidity and mortality were similar between conver-
sion and open repair (OR [95% CI] 1.0 [0.6, 1.7] P  .9780 and 1.3 [0.4,
4.3] P  .6445 for morbidity and mortality, respectively). A similar pattern
among repair groups was demonstrated for log-LOS, with similar LOS for
conversions and open repair which were significantly longer than that
observed for EVAR. No significant demographic or medical risk factor
predictors of conversion were identified.
Conclusions: Conversion was a rare complication affecting 1.1% of
EVAR cases with no broadly identifiable at-risk population. When conver-
sion did occur, morbidity andmortality paralleled those observed for elective
open repair.
A Single Center Experience Comparing Tibial Bypass with Heparin-
Bonded ePTFE vs Saphenous Vein
Richard F. Neville, Avery Capone, Richard Amdur, GeorgetownUniversity,
Washington, DC
Background: Several series have reported that heparin bonded PTFE
(HePTFE) grafts perform in an equivalent manner to saphenous vein (SVG)
for tibial bypass. This series reports a single center, US experience for tibial
bypass using the HePTFE and SVG over a contemporaneous time period.
Methods: A retrospective analysis of prospectively collected data was
conducted for 112 tibial bypasses performed from November 2006 to
January 2009 including 62 HePTFE and 50 SVG. Patient demographics
